Prevention and early detection of prostate cancer

Jack Cuzick, Mangesh A. Thorat, Gerald Andriole, Otis Brawley, Powel H. Brown, Zoran Culig, Rosalind A. Eeles, Leslie G. Ford, Freddie C. Hamdy, Lars Holmberg, Dragan Ilic, Timothy J. Key, Carlo La Vecchia, Hans Lilja, Michael Marberger, Frank L. Meyskens, Lori M. Minasian, Chris Parker, Howard L. Parnes, Sven PernerHarry Rittenhouse, Jack Schalken, Hans Peter Schmid, Bernd J. Schmitz-Dräger, Fritz H. Schröder, Arnulf Stenzl, Bertrand Tombal, Timothy J. Wilt, Alicja Wolk

Research output: Contribution to journalReview article

Abstract

Prostate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control offer opportunities to reduce the risk of developing prostate cancer. Early detection of prostate cancer by prostate-specific antigen (PSA) screening is controversial, but changes in the PSA threshold, frequency of screening, and the use of other biomarkers have the potential to minimise the overdiagnosis associated with PSA screening. Several new biomarkers for individuals with raised PSA concentrations or those diagnosed with prostate cancer are likely to identify individuals who can be spared aggressive treatment. Several pharmacological agents such as 5α-reductase inhibitors and aspirin could prevent development of prostate cancer. In this Review, we discuss the present evidence and research questions regarding prevention, early detection of prostate cancer, and management of men either at high risk of prostate cancer or diagnosed with low-grade prostate cancer.

Original languageEnglish (US)
Pages (from-to)e484-e492
JournalThe Lancet Oncology
Volume15
Issue number11
DOIs
StatePublished - Oct 1 2014
Externally publishedYes

Fingerprint

Early Detection of Cancer
Prostatic Neoplasms
Prostate-Specific Antigen
Biomarkers
Smoking Cessation
Aspirin
Life Style
Oxidoreductases
Pharmacology
Exercise
Weights and Measures
Research

ASJC Scopus subject areas

  • Oncology

Cite this

Cuzick, J., Thorat, M. A., Andriole, G., Brawley, O., Brown, P. H., Culig, Z., ... Wolk, A. (2014). Prevention and early detection of prostate cancer. The Lancet Oncology, 15(11), e484-e492. https://doi.org/10.1016/S1470-2045(14)70211-6

Prevention and early detection of prostate cancer. / Cuzick, Jack; Thorat, Mangesh A.; Andriole, Gerald; Brawley, Otis; Brown, Powel H.; Culig, Zoran; Eeles, Rosalind A.; Ford, Leslie G.; Hamdy, Freddie C.; Holmberg, Lars; Ilic, Dragan; Key, Timothy J.; Vecchia, Carlo La; Lilja, Hans; Marberger, Michael; Meyskens, Frank L.; Minasian, Lori M.; Parker, Chris; Parnes, Howard L.; Perner, Sven; Rittenhouse, Harry; Schalken, Jack; Schmid, Hans Peter; Schmitz-Dräger, Bernd J.; Schröder, Fritz H.; Stenzl, Arnulf; Tombal, Bertrand; Wilt, Timothy J.; Wolk, Alicja.

In: The Lancet Oncology, Vol. 15, No. 11, 01.10.2014, p. e484-e492.

Research output: Contribution to journalReview article

Cuzick, J, Thorat, MA, Andriole, G, Brawley, O, Brown, PH, Culig, Z, Eeles, RA, Ford, LG, Hamdy, FC, Holmberg, L, Ilic, D, Key, TJ, Vecchia, CL, Lilja, H, Marberger, M, Meyskens, FL, Minasian, LM, Parker, C, Parnes, HL, Perner, S, Rittenhouse, H, Schalken, J, Schmid, HP, Schmitz-Dräger, BJ, Schröder, FH, Stenzl, A, Tombal, B, Wilt, TJ & Wolk, A 2014, 'Prevention and early detection of prostate cancer', The Lancet Oncology, vol. 15, no. 11, pp. e484-e492. https://doi.org/10.1016/S1470-2045(14)70211-6
Cuzick J, Thorat MA, Andriole G, Brawley O, Brown PH, Culig Z et al. Prevention and early detection of prostate cancer. The Lancet Oncology. 2014 Oct 1;15(11):e484-e492. https://doi.org/10.1016/S1470-2045(14)70211-6
Cuzick, Jack ; Thorat, Mangesh A. ; Andriole, Gerald ; Brawley, Otis ; Brown, Powel H. ; Culig, Zoran ; Eeles, Rosalind A. ; Ford, Leslie G. ; Hamdy, Freddie C. ; Holmberg, Lars ; Ilic, Dragan ; Key, Timothy J. ; Vecchia, Carlo La ; Lilja, Hans ; Marberger, Michael ; Meyskens, Frank L. ; Minasian, Lori M. ; Parker, Chris ; Parnes, Howard L. ; Perner, Sven ; Rittenhouse, Harry ; Schalken, Jack ; Schmid, Hans Peter ; Schmitz-Dräger, Bernd J. ; Schröder, Fritz H. ; Stenzl, Arnulf ; Tombal, Bertrand ; Wilt, Timothy J. ; Wolk, Alicja. / Prevention and early detection of prostate cancer. In: The Lancet Oncology. 2014 ; Vol. 15, No. 11. pp. e484-e492.
@article{ac532cf28e8847208e2a086082b1240a,
title = "Prevention and early detection of prostate cancer",
abstract = "Prostate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control offer opportunities to reduce the risk of developing prostate cancer. Early detection of prostate cancer by prostate-specific antigen (PSA) screening is controversial, but changes in the PSA threshold, frequency of screening, and the use of other biomarkers have the potential to minimise the overdiagnosis associated with PSA screening. Several new biomarkers for individuals with raised PSA concentrations or those diagnosed with prostate cancer are likely to identify individuals who can be spared aggressive treatment. Several pharmacological agents such as 5α-reductase inhibitors and aspirin could prevent development of prostate cancer. In this Review, we discuss the present evidence and research questions regarding prevention, early detection of prostate cancer, and management of men either at high risk of prostate cancer or diagnosed with low-grade prostate cancer.",
author = "Jack Cuzick and Thorat, {Mangesh A.} and Gerald Andriole and Otis Brawley and Brown, {Powel H.} and Zoran Culig and Eeles, {Rosalind A.} and Ford, {Leslie G.} and Hamdy, {Freddie C.} and Lars Holmberg and Dragan Ilic and Key, {Timothy J.} and Vecchia, {Carlo La} and Hans Lilja and Michael Marberger and Meyskens, {Frank L.} and Minasian, {Lori M.} and Chris Parker and Parnes, {Howard L.} and Sven Perner and Harry Rittenhouse and Jack Schalken and Schmid, {Hans Peter} and Schmitz-Dr{\"a}ger, {Bernd J.} and Schr{\"o}der, {Fritz H.} and Arnulf Stenzl and Bertrand Tombal and Wilt, {Timothy J.} and Alicja Wolk",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/S1470-2045(14)70211-6",
language = "English (US)",
volume = "15",
pages = "e484--e492",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "11",

}

TY - JOUR

T1 - Prevention and early detection of prostate cancer

AU - Cuzick, Jack

AU - Thorat, Mangesh A.

AU - Andriole, Gerald

AU - Brawley, Otis

AU - Brown, Powel H.

AU - Culig, Zoran

AU - Eeles, Rosalind A.

AU - Ford, Leslie G.

AU - Hamdy, Freddie C.

AU - Holmberg, Lars

AU - Ilic, Dragan

AU - Key, Timothy J.

AU - Vecchia, Carlo La

AU - Lilja, Hans

AU - Marberger, Michael

AU - Meyskens, Frank L.

AU - Minasian, Lori M.

AU - Parker, Chris

AU - Parnes, Howard L.

AU - Perner, Sven

AU - Rittenhouse, Harry

AU - Schalken, Jack

AU - Schmid, Hans Peter

AU - Schmitz-Dräger, Bernd J.

AU - Schröder, Fritz H.

AU - Stenzl, Arnulf

AU - Tombal, Bertrand

AU - Wilt, Timothy J.

AU - Wolk, Alicja

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Prostate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control offer opportunities to reduce the risk of developing prostate cancer. Early detection of prostate cancer by prostate-specific antigen (PSA) screening is controversial, but changes in the PSA threshold, frequency of screening, and the use of other biomarkers have the potential to minimise the overdiagnosis associated with PSA screening. Several new biomarkers for individuals with raised PSA concentrations or those diagnosed with prostate cancer are likely to identify individuals who can be spared aggressive treatment. Several pharmacological agents such as 5α-reductase inhibitors and aspirin could prevent development of prostate cancer. In this Review, we discuss the present evidence and research questions regarding prevention, early detection of prostate cancer, and management of men either at high risk of prostate cancer or diagnosed with low-grade prostate cancer.

AB - Prostate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control offer opportunities to reduce the risk of developing prostate cancer. Early detection of prostate cancer by prostate-specific antigen (PSA) screening is controversial, but changes in the PSA threshold, frequency of screening, and the use of other biomarkers have the potential to minimise the overdiagnosis associated with PSA screening. Several new biomarkers for individuals with raised PSA concentrations or those diagnosed with prostate cancer are likely to identify individuals who can be spared aggressive treatment. Several pharmacological agents such as 5α-reductase inhibitors and aspirin could prevent development of prostate cancer. In this Review, we discuss the present evidence and research questions regarding prevention, early detection of prostate cancer, and management of men either at high risk of prostate cancer or diagnosed with low-grade prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84908118271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908118271&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(14)70211-6

DO - 10.1016/S1470-2045(14)70211-6

M3 - Review article

C2 - 25281467

AN - SCOPUS:84908118271

VL - 15

SP - e484-e492

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 11

ER -